Skip to main content

Table 1 Clinical and laboratory features of patients with APS and SLE, and healthy controls

From: Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays

Diagnosis APS (n = 59) SLE/APL+ (n = 60) SLE/APL- (n = 46) HC (n = 40)
Age, mean, years ± SD 46 ± 12 37 ± 11 36 ± 13 31 ± 8
Sex, male/female, n 10/49 1/59 6/40 19/21
VT only, n (%) 31 (52) 5 (8) 10 (21) 0
PM only, n (%) 13 (22) 6 (10)* 10 (25)* 0
VT + PM, n (%) 12 (20) 1 (2)* 3 (7.5)* 0
CAPS, n (%) 3 (5) 0 0 0
Other ARD, n (%) SLE 25 (42) 0 0 0
aCL, mean GPL units 59.7 15.2 13 9
Anti-β2GPI, mean AU 35,5 22 4 3
LA, n (%) 46 (78) 31 (51.7) 0 0
Anti-Thr+, n (%) 21 (35.6) 36 (60) 23 (50) 2 (5)
Anti-FVIIa+, n (%) 5 (8.5) 7 (11.7) 9 (19.6) 2 (5)
Anti-FXa+, n (%) 20 (33.9) 29 (48.3) 23 (50) 0
Anti-PS/Xa+, n (%) 8 (13.6) 20 (33.3) 15 (32.6) 1 (2.5)
  1. *Non-APS miscarriages. Anti-β2GPI, anti- β2-glycoprotein I; aCL, anticardiolipin antibody; APS, antiphospholipid syndrome; aPL, antiphospholipid antibody; ARD, autoimmune rheumatic disease; AU, arbitrary units; CAPS, catastrophic antiphospholipid syndrome; FD, fetal death; FVIIa, factor VIIa; FXa, factor Xa; GPL, IgG phospholipid; HC, healthy control; LA, lupus anticoagulant; Myo, myositis; RA, rheumatoid arthritis; PM, pregnancy morbidity; PS, phosphatidylserine; SLE, systemic lupus erythematosus; SS, Sjögren’s syndrome; SSc, systemic sclerosis; Thr, thrombin; VT, vascular thrombosis.